Chapter 42: Drugs for Heart Failure

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical diagnosis, there's this expectation of precision.

Oh, sure.

Like engineering.

Yeah, exactly.

Like you break your arm, the x -ray shows a jagged white line, and the doctor just points at the screen and says, well, there it is.

Right.

Very cut and dry.

But then you step into the world of cardiology, and suddenly you're looking at a diagnostic landscape that is, honestly, it's a bit more of a slow burn.

It really is.

I mean, heart failure isn't a sudden stop.

No, not at all.

It's a chronic, progressive,

and often fatal disorder where the heart simply cannot pump enough blood to meet the body's metabolic needs.

Exactly.

So today, we are diving into the paradoxical world of the failing heart.

It's a condition where the body's own survival instincts actually become the very things that accelerate its destruction.

Which is fascinating, you know, from a physiological standpoint.

It really is.

Okay.

And if you are an advanced practice nursing or physician assistant student gearing up for clinicals, consider this your ultimate breakdown of heart failure pharmacology.

Yeah, we're taking the dense, complex pharmacotherapeutics of this disease and mapping out again the exactly how to intercept it.

Right.

Our mission for this deep dive is to tackle Chapter 42 of Len's pharmacotherapeutics.

And it is a complex process, but it becomes deeply logical once you see the mechanical through line.

Yeah.

We're going to look at the pathophysiology of the failing heart,

break down the pharmacological arsenal used to treat it, and explore how to actually apply this knowledge clinically using the ACH guidelines.

Because in practice, I mean, understanding the underlying why behind a drugs mechanism makes predicting its effects and its dangers intuitive.

Right.

Rather than just, you know, a raw memorization exercise.

So let's start right at the beginning with the actual physical changes in the heart, specifically in heart failure with reduced ejection fraction or HFREF.

Right.

HFREF.

When the heart sustains an injury, maybe from a massive myocardial infarction or just years of grinding against chronic hypertension,

it doesn't just get weaker, it physically morphs.

Yeah.

That physical morphing is a process called cardiac remodeling.

OK.

So what does that actually look like?

Well, the ventricles dilate, right?

They hypertrophy, meaning the muscle walls thicken and they actually change shape to become more spherical.

Spherical.

So they lose that kind of natural tapered shape.

Exactly.

And a spherical ventricle loses its mechanical advantage.

It's like imagine trying to squeeze a water balloon perfectly evenly from all sides.

Oh, yeah.

That's incredibly inefficient.

The water just bulges out wherever your fingers aren't.

Right.

So this remodeling increases the stress on the ventricular walls and progressively reduces the ejection fraction, which is, you know, the percentage of blood the heart pumps out with each beat.

But the heart doesn't just, like, decide to change shape on its own, right?

No, no.

It's being ordered to do so.

By neurohormonal systems.

Yeah.

So we're talking about the sympathetic nervous system and the renin angiotensin aldosterone system or the RAA.

Yes, the RAAs.

They are actively promoting cardiac fibrosis and myocyte death.

Wow.

So the net result of all this is a progressive decline in cardiac output.

And this is where the story gets really interesting and frankly, a bit tragic.

Tragic because of how the body reacts.

Right.

Exactly.

The body senses that drop in cardiac output and just panics.

It undergoes several physiological adaptations to train fix the problem.

Let's look at those adaptations.

I mean, the initial thought is often,

okay, if the pump is weak, let's just stretch it out so it can snap back harder.

Yeah.

That is the starling mechanism at work.

Like an old rubber band.

Perfect analogy.

When venous pressure increases, it stretches the heart muscle.

Initially, increasing that stretch does increase the force of the contraction, improving stroke volume.

But I'm guessing that doesn't last.

No.

Over time, the muscle fibers become overstretched and damaged.

So the maximal contractile force eventually drops significantly compared to a healthy heart.

It makes me think of a struggling company taking on like high interest payday loans to meet daily operating costs.

I love that analogy.

Right.

Pushing that stretch mechanism or activating those neurohormonal systems gets you the cardiac output you need today.

It keeps the lights on for the afternoon.

Yep.

But the compounding interest of that structural damage is eventually going to bankrupt the entire system.

That payday loan metaphor is perfect for understanding the vicious cycle of maladaptation.

Walk us through that cycle.

Okay.

So when cardiac output falls,

blood pressure naturally drops.

The baroreceptor reflex in the body senses this low pressure and essentially sounds the alarm ramping up the sympathetic nervous system.

So it's dumping adrenaline into the bloodstream.

Exactly.

Basically, it floods the system with adrenaline and noradrenaline to increase the heart rate and clamp down on the blood vessels, which increases vascular resistance.

So now you have a weak, struggling heart and the body just told it to beat faster and push against a brick wall of clamped down arteries.

Right.

And simultaneously, the kidneys notice the reduced blood flow and kidneys are very selfish organs.

They really are.

If they aren't getting blood, they assume the body is dehydrated.

So they activate the RAAS, which leads to massive sodium and water retention.

Which drives up the overall blood volume.

So the compounding interest is piling up.

The body is trying to save the heart, but it is actually drowning it in extra fluid and forcing it to pump against higher resistance.

It is literally working the heart to death.

Wow.

But the heart does have a way to ask for help, right?

Like a biological SOS signal.

It does.

As the atria and ventricles physically stretch from all this extra fluid volume, they release natriuretic peptides, specifically ANP and BNP.

And what do those do?

They're essentially distress hormones that try to counteract the damage.

They promote vasodilation and tell the kidneys, hey, stop holding onto water.

We are drowning up here.

Excrete the sodium.

That is so important for clinical practice.

For anyone listening who will be managing these patients on the floor,

BNP is your compass.

Absolutely your compass.

Circulating BNP levels are a massive predictor of long -term survival in heart failure patients.

Right.

So when you're looking at a patient's chart, trying to decide if they are stable enough for discharge, you are watching that BNP trend.

If it's still sky high, their heart is still screaming for help.

Exactly.

And translating all of this pathophysiology into the patient sitting in front of you clarifies their symptoms.

Because it all connects back to the mechanics.

Right.

That decreased tissue perfusion from the failing pump.

That's why they have profound fatigue and cannot even walk up a flight of stairs.

And the high interest payday loans, the retained fluid and increased venous tone, that explains the peripheral edema.

Swollen ankles, yeah.

And the hepatomegalyous fluid backs up into the liver and the jugular vein distension.

All of it.

So when a patient walks in, how do we actually categorize how far along they are in this bankruptcy process?

Well, clinicians use two primary classification systems that complement each other.

The first is the New York Heart Association, or NYHA Scheme.

This is purely functional and subjective based on how the patient feels.

It ranges from class one, where they have no limitations on physical activity, all the way to class four, where they are experiencing severe symptoms even while resting in a chair.

So NYHA is about symptoms.

And the second one?

The second is the ACAA Scheme, the American College of Cardiology and the American Heart Association.

And this one is different because it doesn't just look at how the patient feels, right?

It stages the progressive nature of the disease itself.

Exactly.

It moves from stage A, meaning the patient is at high risk for heart failure but has no structural damage yet.

Maybe they just have high blood pressure or diabetes.

All the way to stage D.

And stage D is the end of the line, right?

Advanced refractory heart failure requiring highly specialized interventions.

Right.

So the goal, obviously, is to stop a patient from sliding down that slope from stage A to stage D.

And to do that, we have to interrupt that tragic feedback loop.

We have to stop the payday loans.

We do.

Let's talk about the pharmacological arsenal.

We're looking at intercepting the cycle with diuretics, RAS inhibitors, beta blockers, and SGLT2 inhibitors.

Diuretics feel like the most obvious first step for volume overload.

Yeah, they are the immediate plumbing fix.

Makes sense.

By aggressively reducing blood volume, diuretics drop the venous pressure.

They clear out the pulmonary edema so the patient can actually breathe.

And they reduce that harmful cardiac dilation.

So what are our options there?

Well, you have the thiazide diuretics, which produce a moderate amount of urine.

But there is a major catch.

Which is?

Thiazides are largely ineffective if the patient's glomerular filtration rate, their kidney function is low.

Ah.

And in heart failure, kidney function is almost always compromised because of the low cardiac output.

Which is why you have to pull out the heavy artillery loop diuretics, like furosemide.

Furosemide.

Right.

Furosemide produces profound diuresis, and crucially, it still works even when the GFR is low.

It's really the undisputed drug of choice for severe heart failure.

Got it.

And what about potassium -sparing diuretics?

You have those too, but they produce barely any urine on their own.

They are essentially just copilots used to offset the dangerous potassium loss caused by the loop in thiazide diuretics.

Okay, so diuretics are fantastic for keeping a patient comfortable and out of the hospital.

But here is a critical pharmacological reality.

They generally do not prolong survival.

That's right.

They manage the symptoms of the vicious cycle, but they don't stop the structural remodeling of the heart.

For that, we need to inhibit the RAAS.

I really want to dig into that, because I think a lot of students wonder, if diuretics clear the fluid, why is a RAAS inhibitor so essential?

Because the RAAS is what's driving the structural bankruptcy.

Angiotensin -converting enzyme inhibitors, or ACE inhibitors, drugs like captopril and enolapril, are the true MVPs of heart failure therapy.

Why do they work?

They block the production of angiotensin II, which stops the blood vessels from clamping down and decreases the release of aldosterone.

But their secret weapon is that they also suppress the degradation of kinins.

Kinins.

Let's expand on that.

What are kinins?

Kinins are proteins in the blood that cause inflammation and affect blood pressure.

By allowing kinins to accumulate, ACE inhibitors favorably alter cardiac remodeling.

Wait, really?

So they stop the heart from turning into a sphere?

They actually help prevent it.

Yeah, that is why these drugs profoundly prolong life.

Okay, but those accumulated kinins are also responsible for the side effects, aren't they?

They are, unfortunately.

That accumulation in the lungs causes the classic intractable dry cough that drives patients absolutely crazy.

Ugh.

ACE cough.

Right.

And, more dangerously, it can cause angioedema, which is a severe swelling of the face and airway that is a medical emergency.

We also need to flag a massive safety priority here.

ACE inhibitors carry a strict black box warning regarding pregnancy.

Yes.

Very important.

Using them, especially in the second and third trimesters, can cause severe fetal injury and death.

If a patient becomes pregnant, the ACE inhibitor must be discontinued immediately.

And clinicians also have to hyper monitor potassium levels because dropping aldosterone means the body holds onto potassium, risking severe hyperkalemia.

It's a tricky balance.

And dosing is an art form here, right?

Oh, absolutely.

You cannot just start a patient on a massive dose.

You have to start low and slowly titrate upward to the target doses that are actually associated with disease modification.

You have to allow the body to adjust to the shifting hemodynamics.

What if a patient develops that awful, Kenan -induced cough and absolutely cannot tolerate the ACE inhibitor?

Then you pivot to an angiotensin, the second receptor blocker, or an ARB, like Losartan.

Okay.

ARBs are hemodynamically very similar.

They lower blood pressure and reduce afterload, but they don't block the breakdown of Kenans.

So no cough.

Nice.

But is there a downside?

Yeah.

Because you lose that Kenan boost, their protective benefits on cardiac remodeling are considered slightly less robust than ACE inhibitors.

They are the backup quarterback.

But now there's a new starting quarterback changing the guidelines.

The ARNA, or angiotensin receptor, nipple, is an inhibitor.

The drug is Secumetrivolsartan, brand name Entresto.

Entresto is a pharmacological masterpiece.

That's a strong statement.

Why is it a masterpiece?

Well, it combines an ARB to block the harmful effects of the RAAS with Sacubitrol.

Sacubitrol's job is to inhibit an enzyme called neprilicin, and neprilicin normally breaks down those helpful natriuretic peptides we talked about earlier, AMP and BNP.

Oh, wow.

So you are simultaneously blocking the destructive payday loan system while boosting the heart's natural SOS vasodilating hormones.

Exactly.

The clinical trial comparing Entresto to a standard ACE inhibitor, the Paradigm -MHF study, was actually stopped early by the safety committee.

Stopped early.

Not because it was dangerous, but because the reduction in mortality and hospitalizations was so overwhelmingly successful that it was deemed unethical to keep the control group on the older drug.

That is incredible.

I mean, while we are on the RAAS, we have to look at the end of that cascade, aldosterone.

We use aldosterone antagonists like spironolactone and nephronone.

We know aldosterone retains sodium and water, but it has a much darker role in heart failure, doesn't it?

It really does.

As heart failure progresses, the body's aldosterone levels can spike to 20 times normal.

20 times.

Yeah.

And at those levels, aldosterone actively promotes massive myocardial fibrosis, literally scarring the heart tissue, and it screws up the baroreceptor reflex.

By adding an aldosterone antagonist, we block those residual harmful effects, further improving symptoms and prolonging life.

But the safety alert here is severe hyperkalemia.

I mean, if you are already on an ACE inhibitor that holds onto potassium, and you add an aldosterone antagonist that also holds onto potassium,

the patient's blood could become dangerously hyperkalemic, leading to lethal arrhythmias.

Yes.

Renal function and potassium levels must be watched like a hawk.

Also as a weird endocrine side effect, spironolactone can cause painful gynecomastia or breast tissue growth in men.

That's true.

It's something to warn patients about.

Let's transition to a class of drugs that caused a lot of debate for a long time.

Beta blockers like Metaprolol and Carvedilol.

Right.

Because for decades, heart failure was considered an absolute contraindication for beta blockers.

And you can see the logic.

Totally.

Yeah.

You have a patient with a weak failing pump.

Why on earth would you give them a drug that acts as a negative inotrope, a drug specifically designed to reduce the force of contractility?

It sounds like malpractice.

It seems entirely paradoxical.

But the medical community eventually realized that the chronic high dose adrenaline pouring out of the sympathetic nervous system was toxic to the heart.

It was driving the fatal arrhythmias and the remodeling.

Clinical trials finally revealed that shielding the failing heart from that excessive sympathetic stimulation actually allows the heart to recover function over time.

It dramatically improves patient status and prolongs survival.

But you can't just hit them with a full dose.

Because the negative inotropic effect is real.

If you drop their contractility too fast, you'll throw them right into acute cardiogenic shock.

Precisely.

The dosing must start incredibly low, often lower than the starting dose for hypertension, and be titrated up very, very gradually over weeks or months.

Now, there's another heart rate -lowering drug to consider.

Iveridine, or Corlenor.

This is for a very specific subset of patients who are already maxed out on beta blockers, but still have symptomatic heart failure with a resting heart rate over 70 beats per minute.

Yeah, and Iveridine works differently than a beta blocker.

It selectively blocks the specific channels in the sinoatrial node responsible for the cardiac pacemaker current.

So what does that do practically?

It safely drops the heart rate by about 10 beats per minute, increasing the time the heart has to fill with blood during diastole, but crucially it has zero negative inotropic effects.

Meaning it doesn't weaken the physical squeeze of the muscle at all.

Absolutely not at all.

Speaking of surprising drug discoveries, we have to talk about the massive crossover hit of the cardiology world.

SGLT2 inhibitors, drugs like impagliflozin.

Oh yeah.

I mean, this started out purely as a diabetes medication.

It is the ultimate story of following the data.

The original trials, Empirig, Declare -Tymi, Canvas, they were just looking to prove these diabetes drugs were safe for the heart.

Right, a basic safety check.

But the data shocked everyone.

They showed massive relative risk reductions between 27 % and 35 % for heart failure hospitalizations.

That's huge.

How do they work for heart failure?

Well, SGLT2 inhibitors force the kidneys to excrete glucose, which pulls water with it, but they also seem to fundamentally improve myocardial metabolism.

Now they are a foundational pillar of heart failure treatment, even for patients who do not have diabetes.

From the cutting edge to the absolute classics, let's look at the original cardiac glycoside.

Digoxin.

Ah, digoxin.

Derived from the foxglove plant, this drug is a fascinating double -edged sword.

Let's zoom way in on the cellular mechanics here.

Digoxin pockets a specific enzyme on the cardiac cell membrane called the sodium -potassium AT -PACE pump.

Its entire job is to block that pump.

Right, and when that pump is inhibited, sodium can't be pumped out, so it starts accumulating inside the cardiac cell.

Okay, so you have a sodium traffic jam inside the cell.

Exactly.

And because there's a traffic jam of sodium inside,

a secondary exchange process, one that normally trades internal calcium for external sodium grains, to a halt.

The end result is that calcium cannot leave the cell.

And in muscle physiology,

more intracellular calcium equals a harder, more forceful contraction.

It is a powerful positive inotrope.

It is.

But the danger lies in how digoxin interacts with potassium.

This is a lethal dance.

Potassium actually competes with digoxin for binding to that exact same sodium -potassium AT -PACE pump.

Oh, wow.

So what happens if a patient's potassium levels drop, say because they're taking a loop diuretic like furosemite?

Then digoxin suddenly has no competition.

It binds far too easily, flooding the system and causing severe toxicity.

That's terrifying.

And conversely, if potassium levels are too high, it boxes digoxin out, blocking it from the receptor and rendering the drug subtherapeutic.

Right.

Potassium has to be kept in an incredibly tight, normal physiologic range.

Digoxin does provide excellent hemodynamic and neurohormonal benefits, though, right?

It does.

It increases cardiac output, which shuts down the sympathetic nervous system alarm bells, increases urine production, and decreases renin release.

But here is the crucial caveat every clinician must remember.

Yes.

While it reduces symptoms and keeps people out of the hospital, it does not prolong life.

It does not.

And the adverse effects are notorious.

The most dangerous is the risk of dysrhythmias.

Because it messes with the cellular -ion balance, digoxin toxicity can mimic practically any abnormal rhythm.

And if a severe overdose occurs, you have to bring in the antidote.

Fab -antibody fragments, also known as digibind.

But before the lethal arrhythmias hit, the patient will usually exhibit non -cardiac toxicities.

These act as an early warning system.

I equate.

Anorexia, profound nausea, fatigue, and classic neurological visual disturbances, like seeing yellow halos around dark objects.

Some medical historians even theorize that Van Gogh's yellow period was influenced by digitalis toxicity.

Which is wild to think about.

You also have to be hypervigilant about drug interactions.

We already know diuretics cause hypokalemia, risking toxicity.

ACE inhibitors cause hyperkalemia, risking subtherapeutic levels.

And drugs like amiodarone and verabamil can significantly increase plasma levels of digoxin.

The pharmacokinetics make it tricky too.

Digoxin has a frighteningly narrow therapeutic range, optimally .5 to .8 nanograms per milliliter.

And it has a half -life of about 1 .5 days, meaning it takes almost a week to clear the system if toxicity occurs.

So when you're doing patient education, the key takeaway is simple.

Teach your patient how to take their own pulse.

If their heart rate is under 50 beats per minute, or if they notice any change in rhythm, they need to hold the dose and call their provider immediately.

Right.

And briefly, we should also acknowledge the vasodilator combination of isosorbide denatrate and hydrolizine, or BDIL.

This was historically notable as it was the first medication ever proved specifically for a specific ethnic group.

It showed significantly improved outcomes and prolonged life in black patients who remained symptomatic despite optimal therapy with RAAS inhibitors and beta blockers.

OK, so we have all these disparate pieces.

How do we translate this heavy pharmacology into daily practice across the ACHA stages?

Well, stages A and B are all about prevention and arresting the slide.

For stage A patients, those with risk factors like hypertension but no structural damage, you control the blood pressure, lipids, and diabetes, often heavily utilizing an SGLT2 inhibitor.

And then stage B, the patient has structural damage, maybe they had a heart attack, but no heart failure symptoms yet.

The primary goal is to hold remodeling.

This is where you immediately implement an ACE inhibitor and a beta blocker.

Stage C is where the battle really begins.

Structural damage plus active symptoms.

That's four pillars.

Exactly.

This is where you deploy the four pillars of routine therapy.

A diuretic to manage the fluid.

An ACE inhibitor, ARB or ARNI, to stop the neurohormonal remodeling.

A beta blocker to shield the heart from adrenaline and an SGLT2 inhibitor.

And if symptoms persist despite those four?

You can consider adding an aldosterone antagonist or digoxin.

Knowing what not to do in stage C is just as important.

The guidelines are emphatic.

Avoid almost all antidisrhythmics except amiodarone or dofetalide because they have negative inotropic effects that worsen heart failure.

Yep.

Avoid calcium channel blockers which profoundly suppress contractility.

And absolutely avoid NSAIDs, like over -the -counter ibuprofen.

Yes.

An older patient might take ibuprofen for arthritis, not realizing it promotes sodium retention, causes peripheral vasoconstriction, and completely blunts the effects of their diuretics, throwing them right into an exacerbation.

Right.

And when you're evaluating if your treatment is successful in stage C, you have to look at the whole picture.

Base your assessment on physical findings like reduced jugular vein distension or clear lungs and symptoms like improved exercise capacity and dropping BNP levels.

Right.

Don't just stare at the ejection fraction.

Exactly.

Do not rely solely on routine measurements of ejection fraction.

Just because the EF number bumps up slightly doesn't necessarily mean the underlying prognosis has fundamentally changed.

Finally, we reach stage D advanced refractory heart failure.

Here the focus shifts drastically toward end -of -life care, palliative measures, heart transplants or mechanical assist devices.

Continuous intravenous diuretics are often required just to manage the severe fluid overload.

And there is a major clinical trap here.

Beta blockers and ACE inhibitors, the absolute heroes that prolong life in stage C, suddenly pose severe risks in stage D.

Because the heart is just too weak.

Yes.

The heart is so weak that it is entirely dependent on those payday loans, the sympathetic drive and RAAS, just to maintain baseline perfusion.

Blocking them now can cause profound hypotension or immediately fatal cardiogenic shock.

They must be used with extreme caution or discontinued entirely.

Wow.

Treating heart failure truly is a delicate, high -stakes chess game.

You're constantly manipulating hemodynamics, trying to block maladaptive neurohormones and protecting the heart from its own aggressive defense mechanisms, all while dancing around narrow therapeutic windows.

It's not just about making a tired muscle squeeze harder.

It's about outsmarting the body's own reflexes.

It really is.

Before we wrap up, consider the philosophical angle.

If the heart's natural compensatory mechanisms, the very adrenaline and fluid retention reflexes that evolved to keep our ancestors alive after an acute injury or hemorrhage, are exactly what kills us in chronic heart failure, how might this change the way you view the body's healing responses in other chronic disease states?

Oh, that's a great point.

Is the body always as smart as we give it credit for?

That is definitely something to chew on before your next rotation.

Thank you for joining us for this incredibly deep dive into pharmacology.

From all of us at the Last Minute Lecture Team, we wish you the best of luck on your clinicals, your upcoming exams, and your future practice.

Remember, look past the initial symptoms, keep studying the why, and the rest will naturally follow.